WINDTREE THERAPEUTICS INC (WINT) Stock Overview
USA - NASDAQ:WINT - US97382D6004 - Common Stock
WINT Key Statistics, Chart & Performance
The current stock price of WINT is 0.11 USD. In the past month the price decreased by -88.69%. In the past year, price decreased by -99.98%.
WINT Latest News, Press Relases and Analysis
WINT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.53 | 402.76B | ||
| AMGN | AMGEN INC | 13.38 | 157.07B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 150.06B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.66 | 61.26B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.75B | ||
| ARGX | ARGENX SE - ADR | 88.74 | 50.32B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.02 | 34.14B | ||
| INSM | INSMED INC | N/A | 33.75B | ||
| NTRA | NATERA INC | N/A | 26.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.40B | ||
| BIIB | BIOGEN INC | 9.36 | 21.98B |
Related stock screener links
About WINT
Company Profile
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 14 full-time employees. The firm is engaged in the biotechnology business, advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. aPKCi inhibitor platform is a potential high-potency, specific, drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. The firm also has a licensing business model with partnership out-licenses in place. The firm is also focused on environmental services space.
Company Info
WINDTREE THERAPEUTICS INC
2600 Kelly Rd Ste 100
Warrington PENNSYLVANIA 18976 US
CEO: Craig E. Fraser
Employees: 14
Phone: 12154889300
WINDTREE THERAPEUTICS INC / WINT FAQ
Can you describe the business of WINDTREE THERAPEUTICS INC?
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 14 full-time employees. The firm is engaged in the biotechnology business, advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. aPKCi inhibitor platform is a potential high-potency, specific, drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. The firm also has a licensing business model with partnership out-licenses in place. The firm is also focused on environmental services space.
What is the stock price of WINDTREE THERAPEUTICS INC today?
The current stock price of WINT is 0.11 USD. The price decreased by -77.21% in the last trading session.
Does WINT stock pay dividends?
WINT does not pay a dividend.
What is the ChartMill technical and fundamental rating of WINT stock?
WINT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting WINT stock to perform?
6 analysts have analysed WINT and the average price target is 180.54 USD. This implies a price increase of 164027.27% is expected in the next year compared to the current price of 0.11.
What sector and industry does WINDTREE THERAPEUTICS INC belong to?
WINDTREE THERAPEUTICS INC (WINT) operates in the Health Care sector and the Biotechnology industry.
Can you provide the ownership details for WINT stock?
You can find the ownership structure of WINDTREE THERAPEUTICS INC (WINT) on the Ownership tab.
WINT Technical Analysis
WINT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to WINT. WINT may be in some trouble as it scores bad on both profitability and health.
WINT Financial Highlights
Over the last trailing twelve months WINT reported a non-GAAP Earnings per Share(EPS) of -400. The EPS decreased by -236.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.52% | ||
| ROE | -183.17% | ||
| Debt/Equity | 0.01 |
WINT Forecast & Estimates
6 analysts have analysed WINT and the average price target is 180.54 USD. This implies a price increase of 164027.27% is expected in the next year compared to the current price of 0.11.